NASD · Healthcare · Biotechnology · USA
Benitec Biopharma Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for rare diseases. Its lead program, BB-301, is an adeno-associated virus-based gene therapy using a "silence and replace" approach to treat Oculopharyngeal Muscular Dystrophy by permanently silencing disease-causing genes while restoring functional protein expression.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Benitec Biopharma Inc stock.
Not valued: We cannot value this company yet.
13 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on BNTC yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.